GBT Seeks FDA Approval for its qTerm Device - Seite 2

"We seek to have our qTerm human vitals device approved by the FDA to confirm high standards and compliance. Another aspect is to gain potential customer's confidence and trust in the product's performance and accuracy. We plan to offer the technology for personal, hospitals and clinics usage and seeking to comply with the industry's standards and regulations. FDA approval means that the FDA has formally approved the qTerm product to be safe and effective for market and sale in the U.S. Our qTerm device is an external, non-invasive device that is targeted to measure human vitals. In addition, we believe that its main advantage upon similar products is its Artificial Intelligence technology that offers advanced features like real-time health statistics, analytics, and monitoring. The device is designed to assist in potential illness prevention by providing a real time, geographically proximity alert. It is easy for use, and mainly intuitive. We believe that this type of device can become a personal health assistant monitoring, analyzing, and alerting for potential issues in real time. Early detection of potential health issues, based on vitals can be crucial and a life saver. Applying for an FDA clearance is a long process but we strongly believe it will bring our technology to the highest standards to be used by hospitals and individuals," said Danny Rittman, CTO of GBT Technologies.

* Source: FDA - How to Determine if Your Product is a Medical Device | FDA

About Us

GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.